|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 4 (August 15), 1998:
pp. 1206-1218
Expression of Protein Kinase C Isozymes in Human Basophils:
Regulation by Physiological and Nonphysiological Stimuli
By
Katsushi Miura and
Donald W. MacGlashan Jr
From the Johns Hopkins Asthma and Allergy Center, Baltimore, MD.
 |
ABSTRACT |
The expression of protein kinase C (PKC) isozymes in human basophils
and the regulation of PKC isozymes during basophil activation by
phorbol 12-myristate 13-acetate (PMA) ± ionomycin,
f-met-leu-phe (FMLP), and anti-IgE antibody were examined. In human
basophils (> 98% purity), PKC I, II,  , and  were
expressed, PKC was difficult to detect, and PKC and  were
undetectable. In unstimulated basophils, PKCI and II were found
primarily in the cytosol fraction (95% ± 3% of total and 98% ± 1%, respectively). Within 5 minutes of stimulation with PMA (100 ng/mL), both PKCI and II were translocated to the membrane
fraction (85% ± 4% and 83% ± 6%, respectively). In
resting cells, 48% ± 3% and 61% ± 10% of PKC and
, respectively, existed in the membrane fraction. Within 1 minute of
stimulation with PMA, 90% ± 6% of PKC was found in the membrane
fraction, however, no translocation of PKC was apparent. Stimulation
with FMLP caused modest translocation ( 20%) of all PKC isozymes by 1 minute, whereas stimulation with anti-IgE antibody led to no detectable changes in PKC location throughout a 15-minute period of
measurement. However, concentrations of PMA and ionomycin that alone
caused no PKC translocation and little histamine release, together
caused significant histamine release but no apparent PKC translocation.
Studies with bis-indolylmaleimide analogs showed inhibition of
PMA-induced, but not anti-IgE-induced, histamine release. These
pharmacological studies suggest that PKC does not play a
prodegranulatory role in human basophil IgE-mediated secretion.
© 1998 by The American Society of Hematology.
| |
INTRODUCTION |
HUMAN BASOPHILS, AS WELL as human mast
cells, express high-affinity IgE receptors (Fc RI) on their cell
surface and release a variety of mediators1-3 in response
to aggregation of these receptors. Basophils may play an important role
in the allergic inflammatory reaction that follows the initial exposure
to antigen because it has been shown that these cells infiltrate and
secrete their mediators at specific reaction sites in the skin, nose, and lung.4-6 As a participant in these reactions, an
understanding of the mechanisms underlying their activation may be
useful in future therapies. Although many details of FcRI-mediated
signal transduction have become elucidated for mast cell lines such as the rat basophilic leukemia cell (eg, the RBL-2H3), much less is known
about their human counterparts.
In many cell types, protein kinase C (PKC) activation plays a central
role in the early stages of signal transduction. It is often found that
the coapplication of phorbol esters, which are thought to directly
activate PKC enzymes with significant specificity,7 and
calcium ionophores leads to functional behaviors that reasonably mimic
physiological stimulation. A similar result is found for human mast
cells and basophils but with the interesting caveat that phorbol
12-myristate 13-acetate (PMA) alone can induce marked histamine release
in human basophils.8 This does not occur in human lung or
skin mast cells.9 There are unusual characteristics to this
release.8,10 For example, only histamine release results
from PMA stimulation, no LTC4 or IL-4 secretion occurs.11,12 Furthermore, the kinetics of release are very slow compared with other natural secretagogues. PMA-induced release occurs in the absence of extracellular calcium and under conditions where intracellular Ca++ is heavily buffered by an
intracellular chelator like
1,2-bis(o-Aminophenoxy)ethane-N,N,N ,N-tetraacetic acid
(BAPTA; unpublished results). These
observations suggested that the signaling pathway that induces
degranulation in human basophils might be regulated by PKC in a
different way from that in other cells such as human mast cells and
RBL-2H3 cells. However, such results also suggested that histamine
release could result from the activation of PKC(s) alone. The amount of
histamine release associated with activation of basophils through IgE
receptor aggregation, among different preparations of basophils, was
found to be correlated to an increase in membrane-bound PKC-like
activity.13 These results also suggested that PKC
activation may have a role in IgE-mediated histamine release in human
basophils.
PKC may also have a role in downregulating cellular responses, and
studies in RBL cells support this possibility.14-16 In
human basophils, the process of desensitization has been hypothesized to result from the activity of a PKC and recent studies of IL-4 secretion from human basophils also suggest a downregulatory role for
PKC. Activation of PKC(s) with PMA is known to inhibit the cytosolic-free Ca++ ([Ca++] i)
elevation that follows receptor-mediated stimulation. Multiple roles
for PKC are thought to result, in part, from the activity of different
isoforms of PKC and studies in RBL cells support this
perspective.15-17 At present, 12 different PKC isozymes are known.18-22 They are divided into three major groups: the
calcium-dependent or conventional PKC (, I, II, and
), the calcium-independent or novel PKC (, , ,  , and
µ), and the atypical PKC ( and  ).18-22 Marked
differences in tissue distribution exist among the PKC isozymes. PKC
, I, II, , , and have a wide distribution, whereas PKC , , and are restricted to one or a few
tissues.18 Such differences in distribution suggest a
divergence in function between isozymes.23 A role for some
of the PKC isozymes in antigen-induced secretion in RBL-2H3 cells has
been demonstrated.15-17 It was suggested that
antigen-induced secretion was mediated primarily by PKC and and
feedback-inhibition of phospholipase C was mediated primarily by PKC
and .
The conventional PKC , I, II, and contain the
putative Ca2+-binding region C2 in the regulatory domain
and are Ca2+-responsive and dependent on Ca2+
for activity.18,24,25 A role for Ca2+ in the
translocation of conventional PKC induced by phorbol esters was
indicated by the study of the binding of the kinase to plasma membranes
in a cell-free system26 and the study of PKC isozyme translocation induced by calcium ionophore or calcium ionophore plus
phorbol esters in intact cells.27 In human basophils,
phorbol esters and calcium ionophore operate synergistically such that subeffective concentrations of both stimuli induce significant histamine release.10 As a starting point for understanding
the role of PKC in the human basophil response, we have examined which enzymes are present in basophils and characterized the response of the
PKC profile to direct stimulation with phorbol esters. This report then
explores whether changes in the location of these isozymes can be
detected after receptor-mediated stimulation.
Previous studies by our group and others have noted that first
generation PKC inhibitors (eg, H7 and staurosporine) inhibit histamine
release from human basophils stimulated through the IgE receptor.
However, these first generation inhibitors are nonselective, eg,
staurosporine was also found to be a potent inhibitor of tyrosine kinases. Because IgE-mediated secretion in basophils is likely to use
tyrosine kinases early in the signal transduction cascade, as has been
found for RBL cells,28-34 these older studies become ambiguous. One group has also examined a newer PKC inhibitor, calphostin C, and found inhibition of IgE-mediated
release.35 To determine whether some PKC isozymes have
either a positive or negative role in IgE-mediated secretion, the
current studies examine a more recent generation of PKC inhibitors.
With the exception of calphostin C, these inhibitors competively bind
to the catalytic domain of PKC (presumably competing with ATP).
Calphostin C is thought to bind to the regulatory domain, possibly
interfering with activation of PKC by diacylglycerols or phorbol
esters.
| |
MATERIALS AND METHODS |
Reagents.
The following were purchased:
piperazine-N,N-bis-2-ethanesulfonic acid (PIPES),
bovine serum albumin (BSA), ethyleneglycoltetrcetic acid (EGTA),
ethylenediamine tetraacetic acid (EDTA),
D-glucose, human IgG, Phorbol 12-myristate 13-Acetate (PMA),
-mercaptoethanol, NP-40 (Sigma, St Louis, MO); crystallized human
serum albumin (HSA) (Miles Laboratories, Elkhart, IN); fetal calf serum
(FCS) and RPMI 1640 containing 25 mmol/L HEPES (GIBCO-BRL, Grand
Island, NY); Percoll, (Pharmacia, Piscataway, NJ); Tris
(hydroxymethyl)-aminomethane, Tween-20 (Bio-Rad, Hercules, CA);
leupeptin, dithiothreitol, phenylmethylsulfonyl fluoride (PMSF)
(Boehringer Mannheim, Indianapolis, IN); 4-Phorbol 12-Myristate
13-Acetate (4-PMA) (LC Laboratories, Woburn, MA); ionomycin
(Calbiochem, La Jolla, CA). BPO (benzylpenicilloyl)-human serum albumin
(HSA) and BPO-EACA (e-aminocaproic acid) were synthesized as previously
described 36 and the antigen gp120(HIV)-OVA (ovalbumin) was
the gift of Dr Frances Davis of Tanox, Corp (Houston, TX).
Bis-indolylmaleimide I and II, Ro 31-8820, calphostin C and Go-6976
were purchased from Calbiochem.
Antibodies.
Rabbit peptide-specific antibodies (IgG fraction) against PKC I
and and blocking peptides for these antibodies were from GIBCO-BRL.
Rabbit peptide-specific antibodies against , II, , ,
and and blocking peptides for these antibodies were obtained from
Oxford Biomedical Research, Inc (Oxford, MI). The specificity of
antibody binding to specific bands on the Western blots was determined
by either excluding the primary antibodies or blocking primary antibody
binding with the peptides provided by the manufacturer. Two commercial
anti-PKC antibodies were used. They recognize different epitopes
corresponding to residues #662-672 (Oxford) of PKC and #313-326
(GIBCO). Partial genomic analysis has indicated that I and
II isozymes are derived from a single RNA transcript by
alternative splicing and differ from each other only in a short range
of about 50 amino acid residues at the C-terminal V5
region.20 The antibodies we used recognized this region of
each isozyme. Peroxidase-labeled donkey antirabbit Ig antibody was from
Amersham Life Science (Arlington Heights, IL). BPO-specific IgE was
purified from the serum of penicillin allergic patients as previously
described36 and anti-gp120(HIV) IgE was the gift of Dr
Frances Davis of Tanox, Corp.
Buffers and media.
PIPES-albumin-glucose (PAG) buffer contained 25mmol/L PIPES, 110 mmol/L
NaCl, 5mmol/L KCl, 0.1% glucose, and 0.003% HSA. PAGCM was PAG
supplemented with 1 mmol/L CaCl2 and 1 mmol/L
MgCl2. PAG-EGTA was PAG supplemented with 50 nmol/L EGTA.
PAG-EDTA was PAG supplemented with 4 mmol/L EDTA. Countercurrent
elutriation was conducted in PAG containing 0.25% BSA in place of
0.003% HSA.
Basophil purification.
Basophils were purified from residual cells of normal donors undergoing
leukapheresis as previously described.1 The leukocytes were
partially purified by Percoll density gradient and by counter-current elutriation. Basophils were placed into culture (RPMI 1640 with 2% FCS
and 20 µg/mL gentamycin) for 1 hour after elutriation and one
subsequent Percoll separation on a two-step gradient (1.066/1.079). Typically, the last step in the procedure was a two-step Percoll gradient (1.069/1.079) that results in purities greater than 70%. For
these studies, purities ranged from 71% to 90% (median = 80% ± 2%) and for the preliminary studies of basophil PKC profile, these
cells were used for positive selection using anti-IgE antibody. For the
remaining studies, the cells were used without positive selection. To
minimize concerns that the positive selection technique might induce
changes in the PKC status, the entire procedure was carefully performed
below 4°C and the cells were suspended in PAG-EGTA (50 µmol/L).
Proteases (calpains) that induce proteolytic degradation of PKC are
calcium dependent.37 The cells were incubated for 10 minutes with 1 µg/mL mouse antihuman IgE (TES-19) (provided by Tanox
Corp) in the presence of 4 mg/mL normal human IgG to block
FcR.38 After a subsequent 20-minute incubation with
rat-antimouse IgG2a+b paramagnetic beads (8 µL per 107
cells), the cells were passed through a MACS mini-column (MACS system,
Miltenyi Biotec Inc, Sunnyvale, CA). Flow-through cells were collected
and the eluted basophil purities were found to be between 98% to
99.4%. Alcian blue staining was used to assess basophil
purity.39 Cell viability was determined by trypan blue exclusion.
Stimulation of basophils for Western analysis of PKC.
To examine PKC isozyme translocation, the cell preparations were
suspended in PAGCM at a concentration of 1 × 107
cells/mL. Appropriate stimuli were added as described in the Results
and the cells were incubated at 37°C for the indicated times. The
incubations were stopped by a rapid centrifugation and the addition of
4 volumes of ice-cold PAG-EDTA. The cells were then lysed as described
below. To examine PKC isozyme downregulation, basophil preparations
were suspended in RPMI-1640 supplemented with 2% FCS at a
concentration of 5 × 106 cells/mL and incubated with
indicated concentrations of PMA for the indicated times. The cells were
then harvested by centrifugation and the pellet lysed.
Western blot analysis of whole cell lysates.
High-speed cell pellets (~14,000 G for 5 to 10 seconds) were
resuspended at 2 × 107 cells/mL in lysis buffer
(50mmol/L Tris-HCl, pH 7.5, 5 mmol/L EDTA, 10 mmol/L EGTA, 5 mmol/L
dithiothreitol, 1% Nonidet P-40, 1 mmol/L PMSF, 20 µg/mL leupeptin,
100 µg/mL aprotinine, 10 mmol/L benzamidine). After 20 seconds of
vortexing, the cell lysates were kept on ice for 20 minutes and
microfuged for 15 minutes at 4°C. Supernatant was collected as a
protein extract containing lysed cell components without
nuclei.40 Extracts containing equal numbers of basophils (2 × 105 cell equivalents/lane) were diluted with an
equal volume of 2x loading buffer (0.125 mol/L Tris-HCl, pH 6.8, 4%
sodium dodecyl sulfate (SDS) 0.005% bromophenol blue, 20% Glycerol)
(NOVEX, San Diego, CA) containing 0.05% -mercaptoethanol, and
separated by electrophoresis on 4% to 20% Tris glycine
density-gradient gels (NOVEX) (for experiments comparing basophils and
contaminating cells from the same preparations, the samples were loaded
in adjacent lanes). Gels were then transferred to pure nitrocellulose
membrane (Schleicher & Schuell, Keene, NH) by Trans Blot (NOVEX).
Electrophoresis and transfers were performed according to the
manufacturer's recommendations. After transfer, membranes were
immersed in Tris-buffered saline-Tween (TBST; 50 mmol/L Tris, pH 7.5, 0.15 mol/L NaCl, 0.05% Tween-20) containing 5% nonfat
dry skim milk (Carnation, Los Angeles, CA) overnight to block
nonspecific binding. Membranes were then washed three times for 5 minutes with TBST. Immunoreactive proteins were detected using the
isozyme-specific antibodies that were diluted in TBST containing 1%
skim milk as follows: 2 µg/mL for antibodies against I and isozymes; and 1/250 dilution for antibodies against , II,
, , and . After a 4-hour incubation, membranes were washed
with TBST and were incubated with peroxidase-labeled donkey antirabbit
Ig antibody for 1 hour. After five 10-minute washes, membrane-bound
antirabbit Ig antibody was visualized using enhanced chemiluminescence
(ECL) Western blotting detection reagents (Pierce, Rockford, IL), and Hyper-ECL chemiluminescence detection film (Amersham). The ECL films were converted to digital format with a URL
digital camera and the images analyzed with NIH Image (Wayne Rasband,
NIH).1 These studies were designed to obtain a
reasonable estimate of the relative amounts of the PKC isozymes, so the
Western blot technique was evaluated for linearity. Serial dilutions of both PKC standards and cell samples were examined and the relative band
intensities found to be linear if the ECL development was allowed to
proceed for restricted periods of time. These times were optimized for
each gel by exposing the films for several different times and the
exposure chosen that bracketed the range of band intensities. The
comparisons were made on the basis of equal numbers of cells. However,
the protein content of these samples was also found to be equal.
Membrane and cytosol preparation of cells.
After stimulation, medium was removed for assay of histamine (see
below). Cells were suspended at 2 × 107 cells/mL in
ice-cold hypotonic lysis buffer (20 mmol/L Tris-HCl, pH 7.5, 5 mmol/L
EDTA, 5 mmol/L EGTA, 5 mmol/L dithiothreitol, 1 mmol/L PMSF, 200 µg/mL leupeptin, 100 µg/mL aprotinine, 10 mmol/L benzamidine). The
cell suspension was sonicated 3 times at 5-second bursts by an
ultrasonic cell disruptor (Heat System Ultrasonics, Inc, Farmingdale,
NY). After centrifugation at 500g for 5 minutes at 4°C to
remove unlysed cells and the nuclei, the supernatant was centrifuged at
100,000g for 10 minutes at 4°C. The supernatant was
collected as the cytosol preparation (2 × 107 cell
equivalent/mL). The pellet was resuspended at 2 × 107
cell equivalent/mL of hypotonic lysis buffer containing 1% Nonidet P-40 and sonicated. The samples were subjected to Western blot analysis
as described above.
Lactate dehydrogenase (LDH) determination.
To determine the cross-contamination of membrane fractions with
residual cytosolic proteins, the two fractions were analyzed for LDH
content, which should be a cytosolic marker. LDH was measured with a
commercial kit obtained from Sigma. LDH activity in cytosol and
membrane fractions was 14.7 ± 0.5 and 0.28 ± 0.12 mU/106 basophils, respectively (n = 2), indicating that
very little cytosolic protein (1.9% ± 0.7% of total) contaminated
the membrane fraction.
Histamine release and sensitization.
For the pharmacological experiments, basophils were obtained by
venipuncture and partially enriched over a single-step Percoll gradient. The cells were challenged and supernatants were harvested for
analysis by automated fluorimetry.41 Histamine release is expressed as a ratio of sample to total histamine, obtained by lysis of
an equivalent number of cells with perchloric acid, after subtracting
spontaneous release. Purified basophils were processed the same way
when histamine release data were needed. Calphostin C requires
activation by incubation under strong fluorescent lights.42 The experiments with calphostin C were performed in a water bath that
was covered with two 40-watt fluorescent bulbs. Lighting was used
during the preincubation of the cells with the drug as well as during
the challenge phase. Preliminary experiments established that this
lighting was required for adequate potency. For the data analysis in
the pharmacological experiments, the relevant analysis within each
experiment required expressing the amount of inhibition as a fraction
of the control histamine release (cells treated with equivalent
carrier). After expressing the data this way (histamine release from
all samples calculated as a fraction of the response of untreated cells
to stimulus, expressed as a percentage), the results were averaged for
the replicate experiments.
Cytosolic calcium measurements.
Purified basophils were labeled with fura-2AM (1 mmol/L for 25 minutes
at 37°C in RPMI-1640 containing 2% FBS and 0.3 mmol/L EDTA),
washed once with PAG and kept on ice before loading into a
Dvorak-Stotler chamber for observation under the microscope. A field of
30 to 50 cells was monitored by sequential dual excitation, 352 and 380 nm, and ratios of the images were converted to calcium concentrations
according to methods and parameters we have previously published.43 Ratio images were acquired every 3 seconds
early in the reaction and every 10 seconds later in the reaction. The data were compiled for the average of the 50 to 100 cells under observation. In the plots shown, the stimulus was added at the time
point marked zero after obtaining several images before stimulation. Cell perimeters were measured for these fura-2 labeled cells using algorithms previously published.44,45
| |
RESULTS |
Expression of PKC isozymes in human basophils.
To clarify which PKC isozymes were present in basophils, basophils that
were very close to 100% purity were examined; these cells were
obtained by positive selection as described in Materials and Methods.
These studies included a comparative analysis with the contaminating
cells that typically contaminate enriched basophil preparations.
Starting with basophil preparations of 70% to 90% and collecting the
cells that wash through the magnetized mini-MACs column yields
contaminating cells that contain  1% basophils. The subsequently
collected basophils ranged in purity between 98% and 99.4%. The cells
were lysed at a density of 20 × 106/mL and the
equidense solutions were immunoblotted with antibodies specific for
each of the seven isozymes (Fig 1). The
basophil data shown in Fig 1 (right) were expressed as a percentage of the contaminating cell band intensities. Both basophils and
contaminating cells expressed essentially equivalent levels of PKC
I, II and . PKC was expressed at a much higher level
in basophils (452% ± 142%) than that observed in contaminating
cells. Interestingly, PKC was barely detectable in these basophil
preparations (7% ± 3%) compared with contaminating cells. Two
commercial anti-PKC antibodies yielded similar results. PKC was
undetectable in basophils but was present in contaminating cells. PKC
was undetectable in both populations of cells. The data are
normalized for equal cell numbers but an analysis of the protein
content also showed essentially equal levels of protein in the basophil
and contaminating cell lysates. To place the relative values in a more
general context, we compared the band intensities from one preparation
with serial dilutions of PKC isozyme standards. We estimate that PKC
was present at 100 ng/106 basophils and at 14 ng/106 contaminating cells, and PKC was present at 26 ng/106 contaminating cells but not detectable in the
basophil sample used for this particular quantitative comparison.
View larger version (41K):
[in this window]
[in a new window]
| Fig 1.
Expression of PKC isozymes in basophils and contaminating
cells. Basophils (purity: 98% to 99.4%) and contaminating cells (lymphocytes and monocytes) were lysed and subjected to Western blot
analysis as described in Material and Methods. (MWM) Molecular weight
marker (upper band: 97.4 kD, lower band: 68 kD). (R) Rat brain extract.
(B) Human basophils. (C) Contaminating cells (lymphocytes and
monocytes). The blots are representative of five experiments for PKC
and and, three experiments for the other isozymes. The band
intensities were quantified by digital imaging. The data are expressed
as the amount of each isozyme present in basophils expressed as a
percent of the amount in contaminating cells (right panel). The data
represent the mean ± SEM.
|
|
Downregulation of PKC isozymes with overnight PMA treatment.
In many cell types, prolonged treatment with phorbol esters results in
depletion of cellular PKC by proteolytic cleavage that follows
activation37 and often there is a difference in the susceptibility of the various isozymes to downregulation with phorbol
esters.15,18 Purified basophils (purity = 76% ± 3%, n = 4) were cultured for 18 hours with PMA (100 ng/mL) and the cells
lysed for Western blots. In one of these experiments, 4- and 18-hour
time points were examined. PMA completely downregulated PKC I and
II by 18 hours and ~80% downregulation occurred by 4 hours (data
not shown). The downregulation of PKC and was inconsistent
after 18 hours and the changes were not statistically significant (76% ± 18% and 73% ± 14% of the 18-hour incubation without PMA
for PKC and , respectively). The cell viability after overnight
treatment with or without PMA was 92% ± 3% and 94% ± 1%,
respectively (n = 4). As expected, 4-PMA (an inactive analog) did
not induce downregulation of PKC isozymes (data not shown). Marked
downregulation of PKC I and II also occurred with 1 ng/mL (PKC
I and II were 10% and 34% of controls, respectively).
Translocation of PKC isozymes with PMA.
Human basophils (purity = 80% ± 3%, n=4) were incubated with or
without 100 ng/mL PMA for 15 minutes and the asssociation of PKC
isozymes with either membrane or cytosolic cell fractions was examined.
In unstimulated cells, PKC I and II were present in the cytosol
(95% ± 3% of total and 98% ± 1%, respectively) (Fig 2). Fifteen minutes after stimulation,
85% ± 4% of total PKC I and 82% ± 6% of total PKC were
found in the membrane fraction (P < .001 for both I and
II). It should be pointed out that the summation of membrane and
cytosolic PKC band intensities with or without PMA stimulation was not
equal. PMA treatment decreased the total (membrane + cytosol) band
intensities of PKC I and II to 64% ± 10% and 57% ± 5% of control, respectively. However, total PKC and levels were not affected by PMA (96% ± 11% and 99% ± 27% of
control, respectively). These results indicate that the loss of PKC
I and II did not result from poorer recovery because the total
band intensities of PKC and were not changed. Therefore, some
proteolytic cleavage of PKC I and II appears to occur within 15 minutes at this high concentration of PMA.
View larger version (39K):
[in this window]
[in a new window]
| Fig 2.
Translocation of PKC isozymes in basophils stimulated
with PMA. Basophils (purity = 80% ± 3%, n = 4) were incubated
with or without PMA (100 ng/mL) for 15 minutes. The membrane and
cytosol fractions were subjected to Western blot analysis and the band intensities were quantified by digital imaging. The top panel shows a
representative Western blots from one experiment and the lower panel
shows the amount of each isozyme in the cytosol or membrane expressed
as a percentage of either component divided by the sum of both
components [eg, cytoscol/(cytosol + membrane)]. Data are presented
as mean ± SEM for four experiments. * P < .05, ***
P < .001 (paired t-test).
|
|
Compared with PKC I and II, a larger fraction of PKC (48% ± 3% of total) and (61% ± 10%) was located in the
membrane fraction of unstimulated cells. Membrane-associated PKC increased significantly (P < .05) after treatment with PMA.
Similar results were obtained at basophil purities ranging from 75% to
93%, indicating that the small shift was not due to changes occurring
only in contaminating cells (a potential consideration given the
similar levels of expression for this PKC isozyme). However,
translocation of PKC was not apparent and any observed changes were
not statistically significant. 4-PMA did not cause translocation of
these four isozymes nor did it induce histamine release at 100 ng/mL
and 15 minutes of incubation (data not shown). Treatment with 100 ng/mL
PMA induced almost complete translocation of PKC within 1 minute
and translocation of PKC I and II within 5 minutes (Fig 3A). As noted previously, histamine
release after challenge with PMA is slow (requiring at least 60 minutes
to reach 60%8) and the data in Fig 3A reflects this slow
release because a 15-minute incubation with 100 ng/mL resulted in
marginal histamine release (for the four experiments shown in Fig 2,
histamine release was 12% ± 3%). The concentration dependence is
shown in Fig 3B and there were minor differences among PKC , or I
and PKC II.
View larger version (23K):
[in this window]
[in a new window]
| Fig 3.
Time course of PKC isozyme translocation after
stimulation with PMA and the dose-response curve for PMA. In panel A,
basophils were incubated with PMA (100 ng/mL) for the times indicated
(n = 1) and in panel B cells were incubated with various
concentrations of PMA for 15 minutes (n = 1). The membrane and
cytosol fractions were prepared, analyzed by Western blotting, and the
bands quantified by digital imaging. The data are expressed as the
amount of membrane-associated PKC as a percentage of the summed band
intensities for membrane + cytosol. PKC I ( ), II ( ), ( ), ( ), and histamine ( ).
|
|
Receptor-mediated PKC translocation.
Figure 4 shows a PKC translocation study of
basophils stimulated with FMLP (basophil purity = 73%). There were
apparent shifts in location for all four isozymes of PKC. PKC I
showed the greatest translocation whereas there were also smaller
shifts in the location of PKC II, and . With the exception
of PKC , the timing of the changes for each of the isozymes was
similar. Most notably, PKC I, II, and did not shift during
the first 30 seconds of the reaction, whereas PKC showed shifts
that occurred more rapidly, measurable changes occurring at the
earliest time point tested in this experiment, 30 seconds. In a second
FMLP experiment (basophil purity of 81%), no increase in
membrane-associated PKC was evident after 15 seconds although an
increase was evident by 30 seconds as noted in the first experiment. In
contrast, human basophils stimulated with an optimal concentration of
anti-IgE antibody showed no measurable shifts in any of the PKC
isozymes. Figure 5 shows the results from
the best case, basophils treated overnight with IL-3 (10 ng/mL)
followed by stimulation that led to 71% histamine release, a strong
response for an IgE-mediated process. Even under these conditions, no
changes were observed. In three experiments where cells were tested
with or without the overnight incubation with IL-3 but with lesser
secretion, no shifts in the location of the four tested PKC isozymes
were observed. The summation of membrane and cytosolic PKC band
intensities following either FMLP or anti-IgE did not vary with time,
ie, there was no apparent degradation and loss of any of the isozymes
after stimulation in this time frame (data not shown).
View larger version (56K):
[in this window]
[in a new window]
| Fig 4.
PKC translocation in basophils stimulated with FMLP.
Basophils (purity: 73%) were stimulated with 1 µmol/L FMLP and after the times indicated the cells were harvested, membrane and cytosol fractions were prepared, analyzed by Western blotting, and the bands
quantified by digital imaging. The data shows one of two experiments.
The data on the lower panel is expressed as the amount of
membrane-associated PKC as a percentage of the summed band intensities
for membrane + cytosol. PKC I (), II (), (), (), and histamine ( ).
|
|
View larger version (67K):
[in this window]
[in a new window]
| Fig 5.
PKC translocation in basophils stimulated with anti-IgE
antibody. Basophils (purity of 71%) were stimulated with 0.2 µg/mL of anti-IgE antibody and after the times indicated the cells were harvested, membrane and cytosol fractions were prepared, analyzed by
Western blotting and the bands quantified by digital imaging. The
results shown in the top half of the figure are from one of three
experiments, the one with the highest histamine release (71%), and the
bottom half of the figure shows the average of three experiments
(average histamine release was 34%).
|
|
From previous studies we have noted that IgE-mediated histamine release
results from changes in several early signal transduction events that
are quite modest. It has been noted in studies of RBL cells (as well as
many other cell types) that the synergistic effect of several early
signal transduction events is likely to be responsible for observed
levels of antigen-induced secretion. The combination of PMA and a
calcium ionophore such as ionomycin is often used to mimic some of this
synergism. As noted in the one experiment shown in Fig 3B, 1 ng/ml of
PMA did not induce measurable (or marginally measurable) changes in PKC
I or II location. Figure 6 shows the
average results of two experiments in which PKC translocation and
histamine release were examined for cells stimulated with 1 ng/mL PMA,
0.1 µg/mL ionomycin or a combination of the two. PMA at 1 ng/mL and
ionomycin at 0.1 µg/mL alone caused little histamine release (2% ± 1% and 4% ± 3%, respectively), whereas the combination
caused 32% ± 10% histamine release. No translocation of any PKC
isozyme was observed under these conditions, including the combination
of both PMA and ionomycin. The summation of membrane and cytosolic PKC
band intensities did not vary with the conditions, ie, there was no
apparent degradation and loss of any of the isozymes under any of the
conditions tested for the 15-minute period examined (data not shown).
View larger version (32K):
[in this window]
[in a new window]
| Fig 6.
PKC translocation in basophils stimulated with PMA
and/or ionomycin. Basophils (purity: 82% ± 2%, n
= 2 ) were incubated with or without PMA (1 ng/mL) and with
or without ionomycin (0.1 µg/mL) for 15 minutes. Membrane and cytosol
fractions were prepared, analyzed by Western blotting, and the bands
quantified by digital imaging. Data are presented as mean ± range for
two experiments. Histamine release for these samples is also plotted.
|
|
Effects of PKC inhibitors on secretion.
Figure 7 summarizes the data for the five
different PKC inhibitors tested. PMA induces histamine release from
human basophils in the apparent absence of any other costimulus. This
provides a useful test of the ability of these five inhibitors to
inhibit secretion presumably dependent on the activation of PKC. It can be observed in Fig 7A that all of the inhibitors inhibited PMA-induced release with an IC50 of approximately 100 nmol/L (or ~400 nmol/L for
BIS I [Bis-indolylmaleimide I]). In experiments not shown, it was
determined that a 10-minute preincubation with each of these drugs
resulted in inhibition that was the same as 40 minutes of
preincubation. Figure 7B shows that for four of the inhibitors, there
was no inhibition of ionomycin-induced histamine release. Unexpectantly, calphostin C was found to inhibit ionomycin-induced histamine release with an IC50 that was somewhat lower than its IC50
for PMA-induced release. It should be noted that calphostin C also
markedly induced histamine release in the absence of any stimulus such
that at concentrations of 1 µmol/L, spontaneous release increased to
an average of 27% ± 10%. Thus, the apparent inhibition at 1 µmol/L calphostin C was a combination of increased spontaneous
release subtracted from stimulus-induced histamine release that was
also decreased in absolute magnitude at these higher concentrations.
The concentration-dependence of this enhanced spontaneous release was
quite steep such that no enhancement was observed at 300 nmol/L
calphostin C (data not shown).
View larger version (35K):
[in this window]
[in a new window]
| Fig 7.
Effects of various PKC inhibitors on stimulation of
basophil histamine release by PMA (panel A), ionomycin (panel B),
anti-IgE antibody (panel C), and FMLP (panel D). In each panel,
basophils obtained by single step Percoll (low purity) were first
incubated with the inhibitor for 10 minutes before the addition of the
stimulus. After a 45-minute challenge the supernatants were harvested
for histamine analysis. Each panel represents the average of five experiments for each stimulus, () bis-indolylmaleimide I, () bis-indolylmaleimide II, () Ro 31-8220, () Go 6976, and ( ) calphostin C. Control release averaged 58%, 73%, 38%, and 32% for
PMA (30 ng/mL), ionomycin (0.5 µg/mL), anti-IgE antibody (0.2 µg/mL) and FMLP (1 µmol/L), respectively.
|
|
The indolylmaleimide analogs were also found to inhibit the synergy
between PMA and ionomycin. In pilot experiments, basophils were
stimulated with serial twofold dilutions of ionomycin (0.0125 µg/mL
to 0.4 µg/mL) in the presence or absence of several concentrations of
PMA (0.01 ng/mL to 10 ng/mL) to establish the concentration-dependence of the synergism. In these pilot experiments, the ionomycin
dose-response curve in the presence of 0.5 ng/mL to 1 ng/mL PMA was
midway between the curves found for no PMA and 10 ng/mL of PMA. BIS II,
at concentrations of 400 nmol/L, almost completely reversed the synergy
observed when using the combination of 0.6 ng/mL of PMA and the serial dilutions of ionomycin (reducing the response of the cells to the
levels observed with ionomycin alone) and partially reduced the synergy
between 10 ng/mL of PMA and the serial dilutions of ionomycin (data not
shown).
Figure 7C and D shows a summary of the data for the five inhibitors in
cells stimulated with either anti-IgE antibody or FMLP. The surprising
result is that the three indolylmaleimide compounds caused no
inhibition of IgE-mediated histamine release. Indeed, there was an
inconsistent but sometimes marked enhancement of histamine release with
concentrations of BIS II or Ro-31-8220 in the 0.5-10 µmol/L range.
This enhancement was not observed across an anti-IgE antibody dose
response curve, ie, using a single concentration of Ro-31-8220 (1 µmol/L) and several concentrations of anti-IgE antibody, the Ro
compound slightly inhibited supraoptimal concentrations of anti-IgE and
slightly enhanced suboptimal concentrations of anti-IgE (data not
shown). As noted in Fig 7C, there is also a suggestion that Ro-31-8220
enhanced histamine release somewhat better than noted when BIS II was
used, although the variability among donor preparations did not allow
statistical significance to be achieved. This difference between
Ro-31-8220 and BIS II persisted when cells were stimulated with
antigen. The test with antigen differed from a simple dose-response
curve. Basophils were sensitized with serial dilutions of
anti-gp120-IgE such that in the absence of any drug, histamine release
after challenge with an optimal concentration of gp120-OVA conjugate
(50 ng/mL), varied from 10% and 60% according to the concentration of
IgE used for sensitization (320 ng/mL, 800 ng/mL, 2,000 ng/mL, or 5,000 ng/mL). In cells sensitized with low concentrations of IgE, enhancement
with Ro-31-8220 was marked, 2.26- ± 0.37-fold. Although BIS II did
result in statistically significant enhancement, the effects
were modest (1.5- ± 0.15-fold at the lowest sensitization condition, P = .042;
Table 1).
View this table:
[in this window]
[in a new window]
|
Table 1.
Enhancement of Histamine Release by Two
Indolylmaleimides From Basophils Sensitized With Anti-gp120 IgE and
Stimulated With gp120-OVA
|
|
In contrast, both calphostin C and Go-6976 completely inhibited
histamine release. Go-6976 inhibited IgE-mediated histamine release
with an IC50 that was threefold lower than required for inhibition of
PMA-induced release. This observation is readdressed below. All of the
five compounds inhibited FMLP-induced histamine release to varying
extents although, with the exception of calphostin C, the
concentrations required were markedly higher than required for
inhibition of PMA-induced release.
The disparity in results with the indolylmaleimide compounds versus
Go-6976 suggested a problem with the specificity of Go-6976. We
examined whether these compounds had any effect on the IgE-mediated cytosolic calcium response, [Ca++]i. Our
expectation was that there would be no inhibition if the compounds were
acting in ideal manner, inhibition of PKC only. Figure 8A shows that this held true for BIS
II, the kinetic curves for the IgE-mediated
[Ca++]i response were very similar in the
presence or absence of the compound. In a single experiment not shown,
treatment with 2 µmol/L Ro-31-8220 also had no effect on the
[Ca++]i response. On the other hand, Go-6976
completely inhibited the IgE-mediated [Ca++]i
response (Fig 8B). The ability of BIS II to reverse the PMA-induced inhibition of the [Ca++]i elevation that
follows stimulation with anti-IgE antibody was also examined. Figure 8C
shows that BIS II at 400 nmol/L partially reversed this inhibition and
1 µmol/L BIS II almost completely reversed the inhibition. For these
experiments, it was possible to measure another distinct PMA-induced
response: PMA induces morphological changes that are manifested as
flattening and spreading of the cells. Before the stimulation with
anti-IgE antibody in these experiments, cells were incubated ± BIS
II for 10 minutes followed by ± PMA for 5 minutes (see Fig 8
legend). Both preceeding and following the 5 minutes ± PMA, the
cell perimeters were measured. We have previously used this measure to
study shape change in basophils.44,45 For a 5-minute
incubation, 10 ng/mL of PMA induced modest but consistent changes in
the cell perimeters: expressed as a fraction of the starting cell
perimeter, the increase averaged 1.45 ± .02 after PMA. Buffer alone
for 5 minutes shows a slight increase (due to continued cell
attachment) of 1.21 ± .01 whereas pretreatment with BIS II led to a
change similar to buffer alone, 1.23 ± .02. For this endpoint, 400 nmol/L BIS II completely reversed the effect of PMA.
View larger version (22K):
[in this window]
[in a new window]
| Fig 8.
Effect of PKC inhibitors on the
[Ca++]i response to anti-IgE antibody in
basophils. Purified basophils (88% ± 4%) were labeled with fura-2
and analyzed by digital microscopy for changes in [Ca++]i in the presence or absence of the
noted drugs. Panel A shows the results for 400 nmol/L
bis-indolylmaleimide II and panel B the results for 100 nmol/L Go 6976 where the basophils were stimulated with 0.5 µg/mL anti-IgE antibody
(n = 2 for each drug tested). Panel C shows the average results for
three experiments in which basophils were incubated with or without 400 nmol/L BIS II for 10 minutes followed by a 5-minute treatment with or
without 10 ng/mL PMA and then a stimulation with 0.5 µg/mL anti-IgE
antibody. The conditions were (1) neither BIS nor PMA before challenge
with anti-IgE antibody, (2) BIS II before incubation with anti-IgE antibody, (3) PMA before anti-IgE antibody, (4) BIS II (400 nmol/L) before PMA that preceeded anti-IgE antibody, and (5) same as 4 but with
1 µmol/L BIS II.
|
|
| |
DISCUSSION |
These studies first established the presence or absence of
several PKC isozymes in human basophils. PKC is expressed in many
cells,18,19 however, PKC was barely detectable in human basophils compared with contaminating cells (lymphocytes and
monocytes). Basophils expressed only 7% ± 3% of the PKC in
contaminating cells. Studies in human neutrophils and
eosinophils48-50 indicate that PKC is also absent and
the authors of these studies suggest that low levels of platelet
contamination probably contribute to faint banding sometimes observed
for this isozyme. We did not explicitly determine the amount of
platelet contamination in our preparations and although it should be
quite low given the nature of the preparative technique, there is a
possibility that the low level we observed was derived from platelets.
Devalia et al48 has suggested that the PKC isozyme is
specifically downregulated during human neutrophil terminal
differentiation. A similar process may apply to basophils and
eosinophils during their terminal differentiation.
In studies of RBL cells, PKC and PKC appear to have different
roles. Washing permeabilized RBL cells resulted in the loss of PKC
isozymes and the secretory response to antigen. A full secretory
response could be reconstituted by the subsequent addition of PKC and , which suggested that PKC and promoted
exocytosis.15 However, these same studies also suggested
that PKC and had an inhibitory effect on phospholipid
hydrolysis mediated by phospholipase C and probably on
exocytosis.16 Therefore, PKC (and to a lesser extent,
) are suggested to downregulate the response whereas PKC (and
to a lesser extent, ) participates in activating secretion. With
this perspective in mind, the ratio of PKC :PKC in basophils (0.041 ± 0.023 based on calibrated mass measurements) is very low
and leads to the interesting speculation that the absence of PKC eliminates a normally strong downregulatory aspect to PMA signaling,
resulting in PMA-induced histamine release in human basophils.
Other PKC isozymes such as PKC I, II, and are
ubiquitously expressed.18,19 These three isozymes were
expressed in both human basophils and contaminating cells (lymphocytes
and monocytes) (Fig 1). Although PKC s are found in most cells, PKC
I and II are differentially expressed in many
tissues.20,51 Both PKC I and II appeared
equally expressed in human basophils, as in human
neutrophils.49 The band of PKC in contaminating cells was detectable but appears to be expressed at a low level in these cells because it took a 20-minute exposure (ECL detection) to observe a
band. However, it was undetectable in human basophils even after
60-minute exposures. Not surprisingly, PKC was undetectable in both
basophils and contaminating cells because PKC has thus far been
found exclusively in the central nervous system.18,19
On a practical level, these data place some constraints on studies of
PKC isozymes in human basophils. For example, if PKC is present in
basophils, it is clearly not practical to study at this time. With
equal levels of PKC I, II, and , in basophils and
contaminating cells, basophil preparations of greater than 75% should
be used, although it would be preferable to use preparations of greater
than 90%. With respect to PKC , greater than 75% cells should be
adequate (less than 6% contribution from contaminants).
In RBL-2H3 cells, antigen-induced secretion was suppressed by a long
treatment with PMA. This result indicated a possible contribution for
the downregulated PKC isozymes, PKC and , in secretion.
Overnight treatment of human basophils with PMA caused downregulation
of PKC I and II. Unfortunately, treatment with phorbol esters
also causes histamine release from human basophils 8 so
that after overnight treatment with PMA, we could not detect histamine
in the treated cells (data not shown). Therefore, we were not able to
determine the role of downregulated PKC isozymes in histamine release
in human basophils. Studies in progress are examining the ability of
these treated cells to release other mediators.
On treatment of these cells with certain stimuli, a redistribution of
PKC isozymes can be observed. The biological significance of
translocation remains debatable. Translocation to the cellular membrane
has been regarded as equivalent to the activation of the respective PKC
isozyme, therefore, an examination of translocation provides evidence
of which isozymes are involved in certain signal pathway.18
However, in various cell types, rather significant portions of certain
PKC isozymes are constitutively present in the particulate fraction.
This may indicate constitutive activity although in many instances,
this seems unlikely. Thus, the role of membrane-associated PKC isozymes
in unstimulated cells remains unclear. In our studies of human
basophils, PKC I and II were mainly found in the cytosol
fraction in resting cells, and were nearly completely translocated to
the membrane fraction by PMA. These results were also consistent with
the results for PKC in the RBL-2H3 cells,15 Jurkat
cells,40 and other cell types.18 However, a
larger fraction of PKC and existed in the membrane fraction in
unstimulated basophils compared with PKC I and II. Depending on
the cell type, PKC and seem to be differentially distributed
within the cells18 with PKC and often found associated with the particulate fraction.40,52-54 PKC in human basophils was translocated to the membrane fraction by PMA.
However, translocation of PKC was not apparent. These results were
consistent with the translocation of PKC induced by PMA in Jurkat
cells.40 As noted previously, activation of PKC(s) by PMA
itself can induce histamine release from human basophils. Therefore,
with significant translocation of PKC I, II, and to the
membrane fraction, the results support the involvement of these three
isozymes in signals that induce histamine release. However, the
involvement of PKC remains unclear from this type of study but as
noted previously, studies in RBL cells suggest that alterations in PKC phosphorylation occur that may affect function without
translocation.55
The absence of translocation for the isozymes studied after
IgE-mediated stimulation was surprising. Clearly, it was possible to
detect significant changes in PKC I, II, and even PKC after another receptor-dependent event, stimulation with FMLP, although
the changes were modest and occurred after histamine release was
essentially complete. It has been noted previously that the response to
FMLP in these purified basophil preparations is generally more robust
than their response to anti-IgE antibody, but no changes were observed
even with marked levels of anti-IgE-induced histamine release.
However, it is relevant that histamine release could be shown with
combinations of ionomycin and PMA that did not result in measurable
translocation of any of the PKC isozymes studied. It is plausible that
a similar situation occurred after stimulation with anti-IgE antibody.
In addition, not all PKC isozymes have been studied in these
experiments.
If there is translocation of PKC that we could not measure or there is
activation that doesn't require translocation after stimulation with
anti-IgE antibody, PKC inhibitors should inhibit IgE-mediated
secretion, as they do in RBL cells.56 However, the
pharmacological studies raised the possibility that IgE-mediated histamine release is not dependent on a PKC isozyme, or not by an
isozyme known to be inhibited by the indolylmaleimide class of
inhibitors. To arrive at this interpretation, we are required to
dismiss the results with Go-6976 and calphostin C. This seems justified
because it is clear that Go-6976 is inhibiting other kinases (on the
basis of the [Ca++]i studies presented here
and studies in RBL cells57) and because calphostin C seems
to have a multiplicity of effects (including enhancement of spontaneous
release) as well as inhibiting ionomycin-induced release (whereas the
others do not). It is interesting that the core structure of Go-6976
and staurosporine are similar and have the same effect on the
[Ca++]i signal, presumably by inhibiting
tyrosine kinases. Also underlying these pharmacological studies is the
assumption that PMA-induced histamine release from human basophils
reflects the activation of PKC and not some other signaling event (eg,
GTPases) and that this non-PKC event is also inhibitable by the
indolylmaleimide compounds. However, it should be noted that PMA can be
shown to cause other changes in basophils that are thought to be
dependent on PKC activation and that are also well inhibited by the
indolylmaleimide compounds. We have found five other endpoints of PMA
activation: (1) the synergy between PMA and ionomcyin; (2) inhibition
of the IgE-mediated calcium elevation; (3) morphological changes; (4) phosphorylation of cPLA258 (which also occurs following
stimulation with IL-3, anti-IgE antibody, C5a, or fMLP, but
phosphorylation induced by these agents is not inhibitable by the
indolylmaleimides); and (5) inhibition of ionomycin-induced IL-4
secretion.59 The first example may simply be a reflection
of a signaling event also involved in the induction of histamine
release in the presence of PMA alone. However, endpoints 2 and 3 are
generally thought to result from PKC activation. The last two endpoints
(derived from studies that are presented elsewhere) are also thought to result from the activation of PKC but the evidence remains tentative. In each instance, concentrations up to 1 µmol/L BIS II either completely reversed or nearly reversed the PMA-induced effects. Therefore, the indolylmaleimides appear to be effective inhibitors of
PKC-dependent events in basophils and the absence of an inhibitory effect on IgE-mediated release raises questions about the role of PKC
in signaling degranulation in these cells. The bis-indolylmaleimide compounds inhibited FMLP-induced histamine release although the concentrations required ( 3 µmol/L) raise concerns about their selectivity. It is interesting to note that the changes in PKC isozyme
location after FMLP occurred after degranulation was nearly complete.
Taken together, these results also raise questions about the role of
PKC in FMLP-mediated degranulation.
As noted previously, PKC may have a role in both upregulating and
downregulating the activation cascade. Although it seems unlikely that
balanced inhibition of both types of function might result in little
apparent change in the functional endpoint, histamine release, it is
possible the PKC inhibitors had such an effect. At lower levels of
response, especially with antigen, the indolylmaleimide inhibitors
could significantly enhance histamine release, suggesting that if PKC
is regulating release, it may be predominantly active in downregulation
rather than activation. In studies to be published elsewhere, the
indolylmaleimides were not found to inhibit IgE-mediated desensitization. However, recent studies suggest the downregulation events differ when cells are stimulated in the presence or absence of
calcium60 and the ability of the indolylmaleimides to
enhance ongoing secretion might be another reflection of the difference between stimulation in the presence or absence of extracellular calcium. Provided that the effect by indolylmaleimides under these conditions was restricted to PKC, the results suggest that PKC may have
a downregulatory role under these conditions. Previous studies have
suggested that PKC may regulate the duration of the cytosolic calcium
response, however, as shown in Fig 8, inhibition of PKC activity with
BIS II or Ro-31-8220 did not markedly alter the time
course of the calcium response. These results suggest that during
IgE-mediated secretion, the negative influence of PKC may operate on an
unidentified signal transduction pathway. One distinction between
stimulation in the presence or absence of extracellular calcium is a
sustained [Ca++]i response. One might
speculate that the PKC that is active during normal secretion is
calcium dependent. Basophils express little if any PKC but express
easily demonstrable levels of PKC I and II, which may be the
active components in this calcium-sensitive downregulation. However, in
RBL cells, PKC appears to have an opposite role, promoting
secretion, whereas PKC and appear to downregulate
secretion.16,17
Previous studies of PKC activation in basophils relied on an ex situ
assay of PKC activity. At the time, this type of assay used histone III
protein as a target for extracted kinases (cytosol or membrane) and
categorized the measured phosphorylating ability of the extracts as PKC
if the exclusion of phosphatidylserine and Ca++
significantly inhibited the kinase activity. In human
basophils13 and PT18 rat mast cells,61
IgE-mediated increases in this activity were unusual in that only the
membrane component increased, without the usual commensurate decrease
in the cytosolic component. Stimulation with FMLP in human
basophils62 did lead to an increase in membrane activity
with a commensurate decrease in cytosolic activity, more in keeping
with the traditional view of PKC translocation. Without measuring a
known PKC target protein, the IgE-mediated changes in phosphorylation
activity should be interpreted cautiously. In the context of this
paper's results, it is possible that the ex situ phosphorylation
previously noted did not result from the activity of a classical PKC
isozyme. Alternatively, if the enhancement of mediator release observed
with indolylmaleimides indicates inhibition of a PKC activity, the
histone phosphorylating activity previously observed might reflect this
activation of PKC.
In summary, our in vitro studies show that basophils have a profile of
PKC isozymes that differs from lymphocytes/monocytes but is similar to
other granulocytes. Most notably, there was a near absence of PKC ,
no PKC , and a strong presence of PKC . Translocation of some of
these isozymes can be shown after PMA stimulation but not when cells
are stimulated with anti-IgE antibody. It is possible that the combined
action of [Ca++]i elevations and small levels
of translocation that are difficult to detect are sufficient to induce
histamine release. However, pharmacological studies raise the
possibility that if low level changes in PKC translocation
and/or activation occur after stimulation with anti-IgE
antibody, they may be insensitive to the indolylmaleimide compounds or
not be a dominant component of the pro-degranulatory cascade.
| |
FOOTNOTES |
Submitted September 4, 1997;
accepted April 15, 1998.
Supported by NIH Grant No. AI20253.
Address reprint requests to Donald W. MacGlashan, Jr, MD, Johns Hopkins
Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Baltimore, MD
21224; e-mail: dmacglas{at}welchlink.welch.jhu.edu.
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" is accordance with 18 U.S.C. section 1734 solely to indicate this fact.
| |
REFERENCES |
1.
MacGlashan DW,
Jr,
White JM,
Huang SK,
Ono SJ,
Schroeder J,
Lichtenstein LM:
Secretion of interleukin-4 from human basophils: The relationship between IL-4 mRNA and protein in resting and stimulated basophils.
J Immunol
152:3006,
1994[Abstract]
2.
Schroeder JT,
MacGlashan DW Jr,
Kagey-Sobotka A,
White JM,
Lichtenstein LM:
IgE-dependent IL-4 secretion by human basophils. The relationship between cytokine production and histamine release in mixed leukocyte cultures.
J Immunol
153:1808,
1994[Abstract]
3.
Brunner T,
Heusser CH,
Dahinden CA:
Human peripheral blood basophils primed by interleukin-3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation.
J Exp Med
177:605,
1993[Abstract/Free Full Text]
4.
Charlesworth EN,
Hood AF,
Soter NA,
Kagey SA,
Norman PS,
Lichtenstein LM:
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration.
J Clin Invest
83:1519,
1989
5.
Bascom R,
Wachs M,
Naclerio RM,
Pipkorn U,
Galli SJ,
Lichtenstein LM:
Basophil influx occurs after nasal antigen challenge: effects of topical corticosteroid pretreatment.
J Allergy Clin Immunol
81:580,
1988[Medline]
[Order article via Infotrieve]
6.
Guo CB,
Liu MC,
Galli SJ,
Bochner BS,
Kagey-Sobotka A,
Lichtenstein LM:
Identification of IgE bearing cells in the late response to antigen in the lung as basophils.
Am J Respir Cell Mol Biol
10:384,
1993[Abstract]
7.
Castagna M,
Takai Y,
Kaibuchi K,
Sano K,
Kikkawa U,
Nishizuka Y:
Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters.
J Biol Chem
257:7847,
1982[Abstract/Free Full Text]
8.
Schleimer RP,
Gillespie E,
Lichtenstein LM:
Release of histamine from human leukocytes stimulated with the tumor promoting phorbol esters. I. Characterization of the response.
J Immunol
126:570,
1981[Medline]
[Order article via Infotrieve]
9.
Massey WA,
Cohen VL,
MacGlashan DW Jr,
Gittlen SW,
Kagey-Sobotka A,
Lichtenstein LM,
Warner JA:
Protein Kinase C modulates IgE-mediated activation of human mast cells from lung and skin. I. Pharmacologic inhibition.
J Pharmacol Exp Ther
258:824,
1991[Abstract/Free Full Text]
10.
Schleimer RP,
Gillespie E,
Daiuta R,
Lichtenstein LM:
Release of histamine from human leukocytes stimulated with the tumor-promoting phorbol diesters. II. Interaction with other stimuli.
J Immunol
128:136,
1982[Abstract]
11.
Warner JA,
Peters SP,
Lichtenstein LM,
Hubbard W,
Yancey KB,
Stevenson HC,
Miller PJ,
MacGlashan DW Jr:
Differential release of mediators from human basophils: Differences in arachidonic acid metabolism following activation by unrelated stimuli.
J Leukoc Biol
45:558,
1989[Abstract]
12.
Schroeder JT,
MacGlashan DW Jr,
Kagey SA,
White JM,
Lichtenstein LM:
Cytokine generation by human basophils. [Review].
J Allergy Clin Immunol
94:1189,
1994[Medline]
[Order article via Infotrieve]
13.
Warner JA,
MacGlashan DW Jr:
Protein kinase C (PKC) changes in human basophils. IgE-mediated activation is accompanied by an increase in total PKC activity.
J Immunol
142:1669,
1989[Abstract]
14.
Sagi ER,
Lieman H,
Pecht I:
Protein kinase C regulation of the receptor-coupled calcium signal in histamine-secreting rat basophilic leukaemia cells.
Nature
313:59,
1985[Medline]
[Order article via Infotrieve]
15.
Ozawa K,
Szallasi Z,
Kanzanietz MG,
Blumberg PM,
Mischak H,
Mushinski JF,
Beaven MA:
Ca2+-dependent and Ca2+-independent isozymes of protein kinase C mediate exocytosis in antigen-stimulated rat basophilic RBL-2H3 cells: Reconstitution of secretory responses with Ca2+ and purified siozymes in washed permeabilized cells.
J Biol Chem
268:1749,
1993[Abstract/Free Full Text]
16.
Ozawa K,
Yamada K,
Kanzanietz MG,
Blumberg PM,
Beaven MA:
Different isozymes of protein kinase C mediate feedback inhibition of phospholipase C and stimulatory signals for exocytosis in rat RBL-2H3 cells.
J Biol Chem
268:2280,
1993[Abstract/Free Full Text]
17.
Chang EY,
Szallasi Z,
Acs P,
Raizada V,
Wolfe PC,
Fewtrell C,
Blumberg PM,
Rivera J:
Functional effects of overexpression of protein kinase C- , - , - , - , - in the mast cell line RBL-2H3.
J Immunol
159:2624,
1997[Abstract]
18.
Hug H,
Sarre TF:
Protein kinase C isoenzymes: Divergence in signal transduction?
Biochem J
291:329,
1993
19.
Nishizuka Y:
The molecular heterogeneity of protein kinase C and its implications for cellular regulation.
Nature
334:661,
1988[Medline]
[Order article via Infotrieve]
20.
Kikkawa U,
Kishimoto A,
Nishizuka Y:
The protein kinase C family: Heterogenity and its implications.
Annu Rev Biochem
58:31,
1989[Medline]
[Order article via Infotrieve]
21.
Nakamura S,
Nishizuka Y:
Lipid mediators and protein kinase C activation for intracellular signaling network.
J Biochem
115:1029,
1994[Abstract/Free Full Text]
22.
Szamel M,
Resch K:
T-cell antigen receptor-induced signal-transduction pathways activation and function of protein kinase C in T lymphocytes.
Eur J Biochem
228:1,
1995[Medline]
[Order article via Infotrieve]
23.
Dekker LV,
Parker PJ:
Protein kinase C: A question of specificity.
Trends Biochem Sci
19:73,
1994[Medline]
[Order article via Infotrieve]
24.
Nishizuka Y:
Intracellular signaling by hydeolysis of phospholipids and activation of protein kinase C.
Science
258:1992,
1992
25.
Luo JH,
Weinstein IB:
Calcium-dependent activation of protein kinase C. The role of the C2 domain in divalent cation selectivity.
J Biol Chem
268:23580,
1993[Abstract/Free Full Text]
26.
Wolf M,
LeVine H,
May WS,
Cuatrecasas P,
Sahyoun N:
A model for intracellular translocation of protein kinase C involving synergism between Ca2+ and phorbol esters.
Nature
317:546,
1985[Medline]
[Order article via Infotrieve]
27.
Chen CC:
Effect of Ca2+ on the activation of conventional and new PKC isozymes and TPA and endothelin-1 induced translocations of these isozymes in intact cells.
FEBS Lett
348:21,
1994[Medline]
[Order article via Infotrieve]
28.
Benhamou M,
Stephan V,
Gutkind SJ,
Robbins KC,
Siraganian RP:
Protein tyrosine phosphorylation in the degranulation step of RBL-2H3 cells.
FASEB J
5:A1007,
1991
29.
Stephan V,
Benhamou M,
Gutkind JS,
Robbins KC,
Siraganian RP:
Fc epsilon RI-induced protein tyrosine phosphorylation of pp72 in rat basophilic leukemia cells (RBL-2H3). Evidence for a novel signal transduction pathway unrelated to G protein activation and phosphatidylinositol hydrolysis.
J Biol Chem
267:5434,
1992[Abstract/Free Full Text]
30.
Kihara H,
Siraganian RP:
Src homology 2 domains of Syk and Lyn bind to tyrosine-phosphorylated subunits of the high affinity IgE receptor.
J Biol Chem
269:22427,
1994[Abstract/Free Full Text]
31.
Eiseman E,
Bolen JB:
Engagement of the high-affinity IgE receptor activates src protein-related tyrosine kinases.
Nature
355:78,
1992[Medline]
[Order article via Infotrieve]
32.
Jouvin MH,
Adamczewski M,
Numerof R,
Letourneur O,
Valle A,
Kinet JP:
Differential control of the tyrosine kinase lyn and syk by the two signaling chains of the high affinity immunoglobulin E receptor.
J Biol Chem
269:5918,
1994[Abstract/Free Full Text]
33.
Hutchcroft JE,
Geahlen RL,
Deanin GG,
Oliver JM:
Fc epsilon RI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells.
Proc Natl Acad Sci USA
89:9107,
1992[Abstract/Free Full Text]
34.
Yamashita T,
Mao SY,
Metzger H:
Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase.
Proc Natl Acad Sci USA
91:11251,
1994[Abstract/Free Full Text]
35.
Bergstrand K,
Lundquist B,
Karabelas K,
Michelson P:
Modulation of human basophil histamine release by protein kinase C inhibitors differs with secretagogue and with inhibitor.
J Pharmacol Exp Ther
258:824,
1992
36.
MacGlashan DW Jr,
Lichtenstein LM:
Studies of antigen binding on human basophils. I. Antigen binding and functional consequences.
J Immunol
130:2330,
1983[Abstract]
37.
Kishimoto A,
Kajikawa N,
Shiota M,
Nishizuka Y:
Proteolytic activation of calcium-activated, phospholipid-dependent protein kinase by calcium-dependent neutral protease.
J Biol Chem
258:1156,
1983[Abstract/Free Full Text]
38.
Petroni KC,
Schen L,
Guyre PM:
Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-gamma and glucocorticoids.
J Immunol
140:3467,
1988[Abstract]
39.
Gilbert HS,
Ornstein L:
Basophil counting with a new staining method using alcian blue.
Blood
46:279,
1975[Abstract/Free Full Text]
40.
Tsutsumi A,
Kubo M,
Fujii H,
Jose FM,
Turck CW,
Ranson JT:
Regulation of protein kinase C isoform proteins in phorbol ester-stimulated Jurkat T lymphoma cells.
J Immunol
150:1746,
1993[Abstract]
41.
Siraganian RP:
An automated continuous-flow system for the extraction and fluorometric analysis of histamine.
Anal Biochem
57:383,
1974[Medline]
[Order article via Infotrieve]
42.
Tamaoki T,
Takahashi I,
Kobayashi E,
Nakano H,
Akinaga S,
Suzuki K:
Calphostin (UCN1028) and calphostin related compounds, a new class of specific and potent inhibitors of protein kinase C.
Adv Second Messenger Phosphoprotein Res
24:497,
1990[Medline]
[Order article via Infotrieve]
43.
MacGlashan DW Jr,
Warner JA:
Stimulus-dependent leukotriene release from human basophils: A comparative study of C5a and Fmet-leu-phe.
J Leukoc Biol
49:29,
1991[Abstract]
44.
MacGlashan DW Jr,
Bochner B,
Warner JA:
Graded changes in the response of individual human basophils to stimulation: Distributional behavior of early activation events.
J Leukoc Biol
55:13,
1994[Abstract]
45.
MacGlashan DW Jr:
Graded changes in the response of individual human basophils to stimulation: Distributional behavior of events temporally coincident with degranulation.
J Leukoc Biol
58:177,
1995[Abstract]
46.
MacGlashan DW Jr,
Lichtenstein LM:
The transition from specific to nonspecific desensitization in human basophils.
J Immunol
127:2410,
1981[Abstract]
47.
Sobotka AK,
Dembo M,
Goldstein B,
Lichtenstein LM:
Antigen-specific desensitization of human basophils.
J Immunol
122:511,
1979[Abstract/Free Full Text]
48.
Devalia V,
Thomas SB,
Roberts PJ,
Jones M,
Linch DC:
Down-regulation of human protein kinase C alpha is associated with terminal neutrophil differentiation.
Blood
80:68,
1992[Abstract/Free Full Text]
49.
Dang PM,
Rais S,
Hakim J,
Perianin A:
Redistribution of protein kinase C isoforms in human neutrophils stimulated by formyl peptides and phorbol myristate acetate.
Biochem Biophys Res Commun
212:664,
1995[Medline]
[Order article via Infotrieve]
50.
Bates ME,
Bertics PJ,
Calhoun WJ,
Busse WW:
Increased protein kinase C activity in low density eosinophils.
J Immunol
150:4486,
1993[Abstract]
51.
Naor Z,
Shearman MS,
Kishimoto A,
Nishizuka Y:
Calcium-independent activation of hypothalamic type I protein kinase C by unssaturated fatty acids.
Mol Endocrinol
2:1043,
1988[Abstract/Free Full Text]
52.
Borner C,
Buadagno SN,
Fabbro D,
Weinstein IB:
Expression of four protein kinase C isoforms in rat fibroblasts: Distinct subcellular distribution and regulation by calcium and phorbol esters.
J Biol Chem
267:12892,
1992[Abstract/Free Full Text]
53.
Huwiler A,
Fabbro D,
Stabel S,
Pfeilschifter J:
Immunocharacterization of delta- and zeta-isienzymes of protein kinase C in rat renal mesangial cells.
FEBS Lett
300:259,
1992[Medline]
[Order article via Infotrieve]
54.
Ways DK,
Messer BR,
Garris TO,
Qin W,
Cook PP,
Parker PJ:
Modulation of protein kinase C-epsilon by phorbol esters in the monoblastoid U937 cell.
Cancer Res
52:5604,
1992[Abstract/Free Full Text]
55.
Szallasi Z,
Denning MF,
Chang EY,
Rivera J,
Yuspa SH,
Lehel C,
Olah Z,
Anderson WB,
Blumberg PM:
Development of a rapid approach to identification of tyrosine phosphorylation sites: application to PKC delta phosphorylated upon activation of the high affinity receptor for IgE in rat basophilic leukemia cells.
Biochem Biophys Res Commun
214:888,
1995[Medline]
[Order article via Infotrieve]
56.
Yamada K,
Jelsema CL,
Beaven MA:
Certain inhibitors of protein serine/threonine kinases also inhibit tyrosine-phosphorylation of phospholipase Cg1 and other proteins and reveal distinct roles for tyrosine kinase(s) and protein kinase C in stimulated rat basophilic RBL-2H3 cells.
J Immunol
149:1031,
1992[Abstract]
57.
Beaven MA:
Regulation of secretion from secretory cells by protein kinase C
, in Parker P,
Dekker L
(eds):
Protein Kinase C.
Austin, TX, Landes
, 1997
, p 131
58.
Miura K,
Hundley TR,
Hubbard WC,
MacGlashan DW Jr:
Modulation of arachidonic acid generation from human basophils by PKC activation.
J Allergy Clin Immunol
99:S91,
1997
59. Schroeder JT, Lichtenstein LM, Kagey-Sobotka A, MacGlashan DW
Jr: IL-4 secretion by human basophils and lymphocytes is differentially
regulated by protein kinase C activation. J Leukoc Biol (in press)
60.
MacGlashan DW Jr:
Desensitization of IgE-mediated IL-4 release from human basophils.
J Leukoc Biol
63:59,
1998[Abstract]
61.
White JR,
Pluznik DH,
Ishizaka K,
Ishizaka T:
Antigen-induced increase in protein kinase C activity in plasma membrane of mast cells.
Proc Natl Acad Sci USA
82:8193,
1985[Abstract/Free Full Text]
62.
Warner JA,
MacGlashan DW Jr:
Signal transduction events in human basophils A comparative study of the role of protein kinase-C in basophils activated by anti-IgE antibody and formyl-methionyl-leucyl-phenylalanine.
J Immunol
145:1897,
1990[Abstract]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. MacGlashan Jr. and N. Vilarino
Polymerization of actin does not regulate desensitization in human basophils
J. Leukoc. Biol.,
April 1, 2009;
85(4):
627 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Musset, D. Morgan, V. V. Cherny, D. W. MacGlashan Jr, L. L. Thomas, E. Rios, and T. E. DeCoursey
A pH-stabilizing role of voltage-gated proton channels in IgE-mediated activation of human basophils
PNAS,
August 5, 2008;
105(31):
11020 - 11025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Vilarino, K. Miura, and D. W. MacGlashan Jr
Acute IL-3 Priming Up-Regulates the Stimulus-Induced Raf-1-Mek-Erk Cascade Independently of IL-3-Induced Activation of Erk
J. Immunol.,
September 1, 2005;
175(5):
3006 - 3014.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Vonakis, R. Sora, J. M. Langdon, V. Casolaro, and S. M. MacDonald
Inhibition of Cytokine Gene Transcription by the Human Recombinant Histamine-Releasing Factor in Human T Lymphocytes
J. Immunol.,
October 1, 2003;
171(7):
3742 - 3750.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Scheid, M. Huber, J. E. Damen, M. Hughes, V. Kang, P. Neilsen, G. D. Prestwich, G. Krystal, and V. Duronio
Phosphatidylinositol (3,4,5)P3 Is Essential but Not Sufficient for Protein Kinase B (PKB) Activation; Phosphatidylinositol (3,4)P2 Is Required for PKB Phosphorylation at Ser-473. STUDIES USING CELLS FROM SH2-CONTAINING INOSITOL-5-PHOSPHATASE KNOCKOUT MICE
J. Biol. Chem.,
March 8, 2002;
277(11):
9027 - 9035.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Miura, S. Lavens-Phillips, and D. W. MacGlashan Jr.
Localizing a Control Region in the Pathway to Leukotriene C4 Secretion Following Stimulation of Human Basophils with Anti-IgE Antibody
J. Immunol.,
December 15, 2001;
167(12):
7027 - 7037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Miura, S. S. Saini, G. Gauvreau, and D. W. MacGlashan Jr
Differences in Functional Consequences and Signal Transduction Induced by IL-3, IL-5, and Nerve Growth Factor in Human Basophils
J. Immunol.,
August 15, 2001;
167(4):
2282 - 2291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. MacGlashan Jr and S. Lavens-Phillips
Characteristics of the free cytosolic calcium timelag following IgE-mediated stimulation of human basophils: significance for the nonreleasing basophil phenotype
J. Leukoc. Biol.,
February 1, 2001;
69(2):
224 - 232.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
K. Miura and D. W. MacGlashan Jr
Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils
Blood,
September 15, 2000;
96(6):
2199 - 2205.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Huber, M. R. Hughes, and G. Krystal
Thapsigargin-Induced Degranulation of Mast Cells Is Dependent on Transient Activation of Phosphatidylinositol-3 Kinase
J. Immunol.,
July 1, 2000;
165(1):
124 - 133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Miura and D. W. MacGlashan Jr.
Dual Phase Priming by IL-3 for Leukotriene C4 Generation in Human Basophils: Difference in Characteristics Between Acute and Late Priming Effects
J. Immunol.,
March 15, 2000;
164(6):
3026 - 3034.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Miura, J. T. Schroeder, W. C. Hubbard, and D. W. MacGlashan Jr.
Extracellular Signal-Regulated Kinases Regulate Leukotriene C4 Generation, But Not Histamine Release or IL-4 Production from Human Basophils
J. Immunol.,
April 1, 1999;
162(7):
4198 - 4206.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
Abstract
Introduction
Abstract